1. Home
  2. LGIH vs CSTL Comparison

LGIH vs CSTL Comparison

Compare LGIH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$51.14

Market Cap

1.2B

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$41.91

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGIH
CSTL
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
LGIH
CSTL
Price
$51.14
$41.91
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$75.90
$46.00
AVG Volume (30 Days)
439.2K
323.5K
Earning Date
02-17-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.53
N/A
Revenue
$1,788,933,000.00
$343,530,000.00
Revenue This Year
N/A
$2.54
Revenue Next Year
$18.60
N/A
P/E Ratio
$11.30
N/A
Revenue Growth
N/A
10.15
52 Week Low
$39.70
$14.59
52 Week High
$97.25
$43.01

Technical Indicators

Market Signals
Indicator
LGIH
CSTL
Relative Strength Index (RSI) 55.68 66.08
Support Level $50.95 $39.74
Resistance Level $55.28 $43.01
Average True Range (ATR) 3.12 1.72
MACD 0.49 0.06
Stochastic Oscillator 67.06 80.68

Price Performance

Historical Comparison
LGIH
CSTL

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: